Verrica amends credit agreement with OrbiMed; revenue test deferred to Sept 30, 2024

Verrica Pharmaceuticals Inc.

Amendment to Credit Agreement moves revenue test start from earlier date to September 30, 2024.
$500,000 amendment fee paid to lenders in connection with the amendment.
Revenue test determines if principal payments (including premium) are required based on YCANTH net revenue.
No other terms of the Credit Agreement were changed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.